NCT07036614 is a clinical trial in Tracheal Disease, sponsored by Shanghai Chest Hospital.

Who is sponsoring NCT07036614?

NCT07036614 is sponsored by Shanghai Chest Hospital.

What condition does NCT07036614 study?

NCT07036614 studies Tracheal Disease, Bronchial Disease.

Is NCT07036614 still recruiting?

NCT07036614 is currently enrolling by invitation. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT07036614

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Novel Special Light for Endotracheal/Bronchial Lesions.

ENROLLING BY INVITATION Last updated 25 June 2025

What this trial tests

trial in Tracheal Disease in 400 participants. Enrolling by invitation.

Timeline

31 January 2024

Primary endpoint
30 September 2025

30 September 2026

Quick facts

Lead sponsor	Shanghai Chest Hospital
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	400
Start date	31 January 2024
Primary completion	30 September 2025
Estimated completion	30 September 2026
Sites	1 location across China

Conditions studied

Tracheal Disease — all drugs for Tracheal Disease →
Bronchial Disease — all drugs for Bronchial Disease →

Sponsor

Shanghai Chest Hospital

Who can join

18 and older, any sex, with Tracheal Disease or Bronchial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center study. The purpose of this study is o evaluate the diagnostic value of special light (TXI, NBI, RDI) in endotracheal/bronchial lesions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tracheal Disease

Currently open trials in the same condition.

NCT07065565 — Tubeless Tracheal and Carinal Reconstruction · NA · recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07036614 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07036614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing